

24. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. *Arthritis Rheum.* 2012;64(9):3043-3051.
25. Eshwar V, Kamath A. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. *Sci Rep.* 2024;14(1):1222.
26. Davidson L, van den Reek JMPA, Bruno M, et al. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. *Lancet Reg Health Eur.* 2021;13:100266.
27. Alsakarneh S, Al Ta'ani O, Aburumman R, et al. Risk of de novo inflammatory bowel disease in patients with psoriasis and psoriatic arthritis treated with IL-17A inhibitors: a population-based Study. *Aliment Pharmacol Ther* 2025 Apr 7. doi: 10.1111/apt.70139. Epub ahead of print.
28. Lebowitz MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. *J Am Acad Dermatol.* 2018;78(1):81-89.e5.
29. Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Front Immunol.* 2023;14:1294416.
30. Huang PF, Huang TY, Cheng YC, et al. Clinical insights into IL-23 inhibition: risankizumab for Crohn's disease through a systematic review and meta-analysis of randomized controlled trials. *Therap Adv Gastroenterol.* 2025;18:17562848251338743.
31. Long M, Danese S, Ott E, et al. Safety of ustekinumab across approved adult indications: pooled safety analysis in Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis through up to 5 years. Abstract. *Am J Gastroenterol.* 2021;116(1):p S441.
32. Liu R, Li Z, Ye L, et al. Risk of tuberculosis and hepatitis B reactivation in patients with Crohn's disease on ustekinumab: a nationwide real-world study. *Inflamm Bowel Dis.* 2024;30(1):45-52.
33. Honap S, Irving PM, Samaan MA. Ustekinumab-induced inflammatory demyelinating polyneuropathy in a patient with ulcerative colitis. *J Crohns Colitis* 2023;17(1):144-145.
34. Merrill JT, Ginzler EM, Wallace DJ, et al. LBSL02/99 Study Group. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2012;64(10):3364-3373.
35. Xie W, Huang H, Zhan S, et al. Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials. *Lupus Sci Med.* 2021;8(1):e000534.
36. Kim SS, Kiroo KA, Erkan D. Belimumab in systemic lupus erythematosus: an update for clinicians. *Ther Adv Chronic Dis.* 2012;3(1):11-23.
37. Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. *Lupus Sci Med.* 2021;8(1):e000464.
38. McHugh J. Long-term anifrolumab safe in SLE. *Nat Rev Rheumatol.* 2023;19(2):64.
39. Alves C, Penedones A, Mendes D, Marques FB. The Risk of Infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. *J Clin Rheumatol.* 2022;28(2):e407-e414.
40. Szekanecz Z, Buch MH, Charles-Schoeman C, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. *Nat Rev Rheumatol.* 2024;20(2):101-115.

Připravujeme do Klinické farmakologie a farmacie

2025
3

HLAVNÍ TÉMA – Betablokátoři v kardiologii

PŮVODNÍ PRÁCE

- Retrospektivní analýza krvácavých příhod a extrémních INR v populaci zosnulých pacientů

PŘEHLEDOVÉ ČLÁNKY

- Léčba polymorbidních pacientů s roztroušenou sklerózou
- Současná farmakoterapie neuropatické bolesti
- Léčiva ze skupiny ARTA a jejich lékové interakce se zaměřením na antikoagulační

KAZUISTIKA

- Farmakokinetické interakce klozapinu a olanzapinu: kazuistiky lékových změn při inhibici CYP1A2

...a spoustu dalších zajímavých témat...

▼
VYCHÁZÍ
V
ŘÍJNU

 SOLEN
let s vámi